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JOURNAL OF HEPATOLOGYTo the Editor:
We thank Dr. La Mura for commenting on our meta-analysis con-
cerning the impact of insulin resistance (IR) on sustained virolog-
ical response (SVR) in HCV patients treated with pegylated
interferon and ribavirin [1].
We agree that other predictive factors possibly inﬂuencing
SVR rates, such as extensive ﬁbrosis, age, level of viremia, IL28B
polymorphisms, BMI and steatosis [2–4], were not taken into
account. Only a meta-analysis of individual data (frequently
unfeasible) would be able to address this issue. Despite this, it
is likely that IR itself contributes to a reduction in the likelihood
of viral eradication, given the magnitude of the reduction in SVR
rates in patients with IR (20%), its impact regardless of genotype
and absence of heterogeneity.
We also agree that overexpression of suppressors of cytokine
signaling (SOCS-3) induced by HCV may be one mechanism
explaining the non-response to antiviral therapy. The data that
Dr. La Mura presented provide additional arguments supporting
this explanation.
Finally, we agree that, ideally, a dose effect of IR on SVR rates
should be explored. However, such an approach is difﬁcult in that
it assumes that an accurate easy-to-use tool for assessing the sever-
ity of IR is available. Several limitations involved in measuring IR
using the HOMA-IR index have recently been pointed out [5], and
thus it is not certain that the HOMA-IR index is the ideal tool. In
addition, other potential confounding factors again need to be con-
sidered, since the magnitude of the impact of IR on SVR may differ
according to age, ﬁbrosis, etc. Finally, the distinction between
patients with metabolically-related IR and those with HCV-related
IR is crucial, since their respective impacts on SVR ratesmay be dif-
ferent. Therefore, up to now, and despite the limitations discussed
above, the HOMA-IR index measured prior to antiviral therapy
offers an easy way of identifying insulin-resistant patients who
have lower probability of SVR following pegylated bitherapy.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
IBD is associated with an increase in carcinoma in PSC irrespective
of the presence of dominant bile duct stenosisTo the Editor:
We have read with great interest the paper by Rudolph et al.
[1]. The authors have prospectively studied a large cohort of
Primary Sclerosing Cholangitis (PSC) patients for up to two dec-
ades and identiﬁed that only patients with a dominant biliary
stenosis with additional IBD had an increased rate in both bil-
iary and colorectal carcinomas (CRC) compared to patients with
no dominant stenosis or patients with a dominant stenosis
without concomitant IBD. Their ﬁndings suggest that the occur-Journal of Hepatology 2rence of additional IBD in PSC patients has a carcinogenic
potential and also results in reduced survival free of liver
transplantation. The authors recommend that these patients
should be carefully screened for bile duct, gallbladder and colo-
rectal carcinomas. We would here like to present our data on
an equally large cohort of PSC patients, with a similar follow-
up, which does not substantiate their ﬁndings.
Two hundred and forty-one PSC patients (161 men, median
age of diagnosis 34 years) with an established diagnosis of PSC,012 vol. 57 j 467–477 473
duct stenosis warrants careful investigation irrespective of IBD
status [5].
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Table 1. Inﬂuence of inﬂammatory bowel disease (IBD) on the frequency of
colorectal and biliary carcinomas in PSC patients with and without dominant
strictures.
Colorectal
carcinoma
Biliary 
carcinoma
Total p value*
No dominant stenosis
No IBD, n = 59 1 1 2
IBD, n = 105 6 3 9 0.330
Dominant stenosis 
No IBD, n = 22 0 1 1
IBD, n = 55 5 8 13 0.095
All patients
No IBD, n = 81 1 2 3
IBD, n = 160 11 11 22 0.016
⁄Data were analyzed using the Fisher exact test or Chi-square test when appro-
priate, comparing the combined frequency of colorectal carcinoma and biliary
carcinoma in PSC patients with IBD versus PSC patients without IBD.
Letters to the Editor
who were seen at the department of Gastroenterology and
Hepatology at the University Medical Center Groningen
(UMCG), the Netherlands, between January 1990 and January
2010 were included in the study. The cohort has recently been
described [2]. The UMCG is one of the three centers for liver
transplantation in the Netherlands and is therefore a tertiary
referral center. Robustness of the diagnosis of PSC was checked
with an expert hepatologist (A.P. van den Berg or E.B. Haagsma,
UMCG). All electronic patient records of the PSC patients were
systematically reviewed for the following data: gender,
ethnicity, date of birth, date of diagnosis of PSC, method of
diagnosis, presence of symptoms at onset, presence of
dominant biliary strictures, presence of colorectal, biliary
or hepatic malignancy, presence and onset of IBD, evidence
of other immune-mediated diseases, date of liver transplanta-
tion, date and cause of death, and date of last follow-up.
Follow-up ended at the date of liver transplantation, death,
date of the last visit to the clinic, in case patients were
lost-to-follow-up, or end-of-study date (January 2010). Mean
follow-up was 6.2 (0.0–29.5) years.
In the whole cohort, 12 CRCs and 13 biliary malignancies
(10 cholangiocarcinoma, three gallbladder carcinoma) devel-
oped during the study period. None of these individuals were
diagnosed with biliary cancer at time of PSC diagnosis. The
results are depicted in Table 1, stratiﬁed for the occurrence
of concomitant IBD and dominant strictures. In three patients,
dominant strictures were identiﬁed by MRCP and conﬁrmed
by ERCP. In all the other patients, dominant strictures were pri-
marily identiﬁed with ERCP.
Our results differ from the data presented by Rudolph et al.
and we could not conﬁrm their ﬁnding that in IBD cases with
dominant stenosis the risk for both CRC and biliary carcinoma
is increased compared to the IBD group without dominant
stenosis. The ﬁrst main difference is the number of 11 malig-
nancies (seven CRC and four biliary malignancies) we observe
in the group without dominant stenosis (irrespective of IBD sta-
tus) compared to only one case in the paper of Rudolph et al.
The second difference is that we did observe a case of biliary
malignancy in a patient without IBD. Overall, the cancer risk
in the entire cohort seemed to be more dependent on concur-
rent IBD than the combination of concurrent IBD and a domi-
nant biliary stricture. The increased cancer risk in PSC with
IBD group has recently also been observed in another cohort
from New Zealand [3].
We do want to emphasize that our data has been collected
retrospectively in contrast to the well-designed prospective col-
lection of the study of Rudolph et al. Moreover, difﬁculties in
deﬁnitions of dominant biliary strictures could introduce bias.
On top of that, increasing clinical and genetic evidence suggests
that PSC-IBD is a distinct phenotype which is difﬁcult to distin-
guish from the PSC – no IBD subgroup [4].
The data presented by Rudolph et al. indeed show a
statistical association for an increased risk of malignancy
development in cases with IBD and a dominant stenosis.
However, we could not conﬁrm this in a similar sized cohort.
Moreover, their association does not imply causality and no
biological or pathogenetic explanation is given in their
paper. We do believe that surveillance strategies should be
conducted based on recently published guidelines for CRC
and biliary carcinomas and want to stress that dominant bile474 Journal of Hepatology 2012 vol. 57 j 467–477
